Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 5
2004 3
2005 2
2006 1
2009 2
2010 5
2011 11
2012 10
2013 4
2014 6
2015 2
2016 3
2017 10
2018 12
2019 11
2020 9
2021 7
2022 9
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: laverman gd. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
The COOPERATE trial.
Vogt L, Laverman GD, de Zeeuw D, Navis G. Vogt L, et al. Among authors: laverman gd. Lancet. 2003 Mar 22;361(9362):1055-6. doi: 10.1016/S0140-6736(03)12803-6. Lancet. 2003. PMID: 12660079 No abstract available.
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
Laursen JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Frimodt-Møller M, Laverman GD, Kooy A, Persson F, Heerspink HJL, Hansen CS, Rossing P. Laursen JC, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Oct;25(10):3064-3067. doi: 10.1111/dom.15180. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385968 Clinical Trial. No abstract available.
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Sen T, et al. Among authors: laverman gd. Diabetes Obes Metab. 2022 Aug;24(8):1578-1587. doi: 10.1111/dom.14729. Epub 2022 Jun 1. Diabetes Obes Metab. 2022. PMID: 35478433 Free PMC article. Clinical Trial.
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Rotbain Curovic V, Houlind MB, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Tavenier J, Eugen-Olsen J, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL. Rotbain Curovic V, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Nov;25(11):3152-3160. doi: 10.1111/dom.15209. Epub 2023 Jul 7. Diabetes Obes Metab. 2023. PMID: 37417375 Clinical Trial.
117 results